Trials / Completed
CompletedNCT00646035
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety and efficacy of paricalcitol capsules as compared to placebo for treatment of secondary hyperparathyroidism by decreasing serum intact parathyroid hormone levels in end stage renal disease subjects on peritoneal dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paricalcitol capsules | baseline iPTH/60 |
Timeline
- Start date
- 2002-01-01
- Primary completion
- 2002-11-01
- First posted
- 2008-03-28
- Last updated
- 2008-03-28
Locations
24 sites across 2 countries: United States, Poland
Source: ClinicalTrials.gov record NCT00646035. Inclusion in this directory is not an endorsement.